Discussion
In this study, we demonstrate that hypothermia in severely blunt injured patients is associated with development of CCI but not associated with increased risk of death which recapitulates earlier work on this subject.26 Our early transcriptional analysis also found a significant, broad downregulation in several gene pathways from circulating monocytes, but not lymphocytes or neutrophils, in hypothermic patients compared with normothermic patients. This is a critical and novel finding demonstrating specific cellular effects of hypothermia. Mixed-cell population analysis did not demonstrate this downregulation, which only became significant in granular analysis of specific cell lines. These data indicate hypothermia may be a major driver of CCI by way of dysregulating immune function early and sustained for several weeks following initial injury. Importantly, the sustained downregulation in the ability for monocytes to present antigen may result in late infectious complications, in addition to the independent association of the genomic changes induced by hypothermia.
The changing epidemiology of trauma morbidity and mortality warrants investigation about the nature of late adverse outcomes. The patients who benefit from improved early mortality are now surviving their initial trauma only to die many weeks later.4 21 23 24 40 It follows that there may be lasting alterations in these patients’ physiology, and PICS is an emerging phenotype which may underlie this phenomenon. This study demonstrated a clear association between hypothermia and the clinical entity of CCI, which appears to be associated with ongoing organ failure or death even when controlling for other markers of severe injury early in trauma, including shock, coagulopathy and blood transfusion.
Hypothermia in severely injured patients is closely linked to other drivers of mortality and long-term morbidity, including shock and coagulopathy, making analysis of the impact of each individual factor on CCI more difficult. However, when correcting for shock and coagulopathy, hypothermia remained an independent factor associated with the development of CCI in both cohort of patients. Furthermore, we evaluated the interaction of these three terms together and did not find their interaction greatly influenced by the results of our model. Importantly, although continued improvement in resuscitation and clinical care continued, the most recent cohort supports this unique finding of hypothermia altering inflammation and being associated with CCI. Together, these clinical data support the novel genomic data showing significant changes selectively within monocytes early on following severe injury and hypothermia. Because of the confounding direct effect of hypothermia and transfusion, an additional regression analysis was performed that included an interaction between RBC transfusions. This analysis supported hypothermia being independently associated with CCI despite the potential contribution of blood transfusion. Interestingly, hypothermia was not independently associated with mortality. This finding is intriguing and suggests the CCI associated with hypothermia is driven by sustained organ dysfunction and not death. Thus, the direct effects on inflammation and sustained inflammatory alterations demonstrated in the genomic analysis suggests a potential role of hypothermia on sustained organ dysfunction.
The findings of this study are important because the initial inflammatory genomic dataset is the largest cohort to date that contains linked clinical data to multiple time-point transcriptomic data. Demonstrating and validating the initial and sustained inflammatory contribution to hypothermia, and development of sustained inflammatory clinical dysfunction in CCI is important in determining potential long-term effects of a relatively frequent clinical event in hypothermia. Although CCI is likely multifactorial in nature, it appears that hypothermia may be a critical and potentially modifiable factor involved. Our analysis when controlling for several key covariants demonstrated a strong association between hypothermia, immune dysregulation and CCI.
The overall immunological response to trauma is remarkably complex and remains poorly understood. The changes in inflammatory mediators, antigen presentation, T cell proliferation and function and natural killer cell function seen following trauma are similar to changes seen following low-dose bacterial endotoxin injection and appear to begin at the time of injury.14 41 This is consistent with a hypothesis of non-resolving inflammation, but immunosuppression is also present following sepsis and trauma indicating these states actually lead to a mixed inflammatory picture.42 43 Because this study demonstrated immunological changes early following injury, there is a plausible role for hypothermia in these alterations. The changes, however, are specific and only occurred in circulating monocytes without changes in neutrophils or lymphocytes. This finding provides evidence that the immune response to trauma likely represents a fundamental, initial genomic response to severe inflammation and the acute onset of a chronic inflammatory phenotype that is affected by the initial clinical state. The early transcriptomic response in these hypothermic patients clearly shows a gross global dysregulation in inflammatory genes that appears to wane gradually with time but that persists up to 4 weeks and potentially longer after injury. Among the initial changes is an upregulation of pro-inflammatory cytokines that is associated with a concurrent downregulation of antigen presentation, in particular of MHC II genes. This immune dysregulation may result in persistent immune dysfunction, PICS, severe infections and late death following discharge.7 44 The available data currently hint that these changes start quite early after injury, and thus the opportunity to intervene on CCI by correcting hypothermia may improve outcomes.45 This emphasizes the need to better understand the relative importance of hypothermia on genomic expression in immune regulation and the association with clinical outcome and long-term complications.
There are a number of key limitations to this study which contextualize these findings and clarify how to optimally apply the results. While these data were analyzed retrospectively, the initial cohort of data was prospectively collected from the largest multicenter trauma database that includes admission vital signs and matched blood samples making it the optimal available study population for long-term physiological and inflammatory effects of hypothermia. Nevertheless, the study was not designed to collect enough blood samples at predetermined intervals on enough hypothermic patients to make causal conclusions beyond the associations described here. Additionally, although variations in clinical practice could potentially affect these results, the effects of changes in resuscitation practice and recent clinical care were supported by the recent validation cohort. Furthemore, the temperature of 34.5°C was used as the cut-off for admission hypothermia as it is a common cut-off in clinical trauma papers despite being warmer than 32°C, which is the temperature that animal studies suggest is associated with a significant impairment in clotting function.46 47 Still, both of these cohorts represent a large, pragmatic, heterogeneous trauma population that is broadly sampled and contains clinically meaningful physiology markers. Regarding the utility of studying admission hypothermia as a modifiable risk factor, it is true that correcting body temperature prior to arrival in the ED can be challenging; however, early intervention on hypothermia does represent a target for intervention. It is interesting that transfer status in the validation cohort and thus sustained hypothermia was independently associated with CCI, but the role of rewarming and duration of shock was not able to be separated within this specific cohort. Our future work focuses on rewarming techniques, rate of rewarming and their effect on CCI.
With respect to the genetic analysis, we analyzed the transcriptomic response of circulating monocytes, neutrophils and lymphocytes, but compartmentalization of the inflammatory response is a well-known phenomenon. Importantly, while we were not able to clearly see recapitulated transcriptomic changes in neutrophils or leukocytes, we did uncover a detailed and likely important cell-line-specific transcriptome change. We were unable to investigate the transcriptome of these cells in secondary lymphoid organs and the reticuloendothelial system which would have allowed more granular topography about the time and location of transcriptomic changes. Additionally, as patients convalesced, the sampling intervals became longer, potentially missing brief secondary immunological responses. Finally, as other parts of clinical practice evolve including resuscitation and critical care, the isolated effect of hypothermia may be altered. Thus, this study similar to the retrospective nature of this analysis is subject to potential current and future changes in practice. However, the specific contribution of hypothermia remains important.
The past 50 years of trauma care has been marked by continuous improvement in prehospital, operative and ICU care targeted at managing the lethal triad of acidosis, coagulopathy and hypothermia.5 Patients who survive longer after their initial trauma are at risk for long-term physiological changes and disability. As our ability to keep patients alive through their acute resuscitation improves, identifying and correcting risk factors for poor long-term outcomes is increasingly imperative. Admission hypothermia does appear to be independently associated with CCI following traumatic injury, and this work illuminates immune dysregulation as a possible mechanism for this delayed clinical syndrome. Significant future investigation will shed light on the important impacts of rapid correction of hypothermia on the host immune response and delayed outcomes.